Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations
Year: 2014
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
Authors: Lisa Zimmer, Fabrice Barlesi, Maria Martinez-Garcia, Veronique Dieras, Jan H.M. Schellens, Jean-Philippe Spano, Mark R. Middleton, Emiliano Calvo, Luiz Paz-Ares, James Larkin, Simon Pacey, Miro Venturi, Françoise Kraeber-Bodéré, Jean J.L. Tessier, Wilfried Ernst Erich Eberhardt, Michel Paques, Ernesto Guarin, Valerie Meresse, Jean-Charles Soria
Institutions: University of Duisburg-Essen, Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Hospital Del Mar, Municipal Institute for Medical Research, Hospital del Mar Research Institute, Institut Curie, The Netherlands Cancer Institute, Pitié-Salpêtrière Hospital, Université Pierre-et-Marie-Curie, Churchill Hospital, Hospital Universitario Virgen del Rocío, Royal Marsden NHS Foundation Trust, University of Cambridge, Roche Pharma AG (Germany), Centre Hospitalier Universitaire de Nantes, F. Hoffmann-La Roche AG, Ruhrlandklinik, Essen University Hospital, Centre hospitalier national d'ophtalmologie des Quinze-Vingts, Centre d'investigation clinique Quinze-Vingts, Institut Gustave Roussy
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2054913636
